Methotrexate microparticle encapsulated- Hubei Soundny Bio-Tech

Drug Profile

Methotrexate microparticle encapsulated- Hubei Soundny Bio-Tech

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hubei Soundny Bio-Tech CO., LTD
  • Developer Hubei Soundny Bio-Tech; Xiangyang Central Hospital
  • Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Non-small cell lung cancer

Most Recent Events

  • 23 Aug 2017 Chemical structure information added
  • 10 May 2017 Clinical trials in Non-small cell lung cancer (Newly diagnosed) in China (unspecified route) (ChiCTR-ONC-17012168)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top